Literature DB >> 12690306

Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment.

Daniel A Vorobiof1, Bernardo L Rapoport, Rabia Mahomed, Margaret Karime.   

Abstract

Fourteen patients with metastatic malignant melanoma that had failed to respond to standard dacarbazine-based chemotherapy treatment were entered into a phase II study of pegylated liposomal doxorubicin (Caelyx) given as a single intravenous injection at a dose of 50 mg/m(2) at 28 day intervals. No objective responses were documented. Treatment was well tolerated. We conclude that pegylated liposomal doxorubicin does not demonstrate sufficient activity in metastatic melanoma to warrant further investigation in this setting.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12690306     DOI： 10.1097/00008390-200304000-00015

Source DB:  PubMed          Journal:  Melanoma Res        ISSN： 0960-8931            Impact factor:   3.599


  8 in total

1.  Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model.

Authors:  Thomas Enzler; Yasuyo Sano; Min-Kyung Choo; Howard B Cottam; Michael Karin; Hensin Tsao; Jin Mo Park
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

Review 2.  Engineering nanomedicines for improved melanoma therapy: progress and promises.

Authors:  Di Bei; Jianing Meng; Bi-Botti C Youan
Journal:  Nanomedicine (Lond)       Date:  2010-11       Impact factor: 5.307

3.  A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma.

Authors:  Michael G Smylie; Ralph Wong; Catalin Mihalcioiu; Chris Lee; Jean-Francois Pouliot
Journal:  Invest New Drugs       Date:  2006-09-07       Impact factor: 3.850

4.  ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.

Authors:  Yuchun Luo; Katiuscia Dallaglio; Ying Chen; William A Robinson; Steven E Robinson; Martin D McCarter; Jianbin Wang; Rene Gonzalez; David C Thompson; David A Norris; Dennis R Roop; Vasilis Vasiliou; Mayumi Fujita
Journal:  Stem Cells       Date:  2012-10       Impact factor: 6.277

Review 5.  The history and future of chemotherapy for melanoma.

Authors:  Arvin S Yang; Paul B Chapman
Journal:  Hematol Oncol Clin North Am       Date:  2009-06       Impact factor: 3.722

6.  Tissue-protective activity of selenomethionine and D-panthetine in B16 melanoma-bearing mice under doxorubicin treatment is not connected with their ROS scavenging potential.

Authors:  Rostyslav R Panchuk; Nadia R Skorokhyd; Yuliya S Kozak; Liliya V Lehka; Andrey G Moiseenok; Rostyslav S Stoika
Journal:  Croat Med J       Date:  2017-04-14       Impact factor: 1.351

7.  Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment.

Authors:  Emilia Licarete; Valentin Florian Rauca; Lavinia Luput; Denise Drotar; Ioana Stejerean; Laura Patras; Bogdan Dume; Vlad Alexandru Toma; Alina Porfire; Claudia Gherman; Alina Sesarman; Manuela Banciu
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

8.  Hyperthermia Enhances Doxorubicin Therapeutic Efficacy against A375 and MNT-1 Melanoma Cells.

Authors:  Diana Salvador; Verónica Bastos; Helena Oliveira
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.